First Bank & Trust Invests $1.10 Million in Bristol-Myers Squibb (NYSE:BMY)

First Bank & Trust bought a new position in Bristol-Myers Squibb (NYSE:BMY) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 20,207 shares of the biopharmaceutical company’s stock, valued at approximately $1,096,000.

A number of other hedge funds have also bought and sold shares of BMY. Saratoga Research & Investment Management purchased a new stake in shares of Bristol-Myers Squibb during the 1st quarter valued at about $201,000. Grimes & Company Inc. grew its stake in shares of Bristol-Myers Squibb by 10.3% during the 1st quarter. Grimes & Company Inc. now owns 380,641 shares of the biopharmaceutical company’s stock valued at $20,642,000 after acquiring an additional 35,677 shares during the period. WoodTrust Financial Corp grew its stake in shares of Bristol-Myers Squibb by 38.4% during the 1st quarter. WoodTrust Financial Corp now owns 13,726 shares of the biopharmaceutical company’s stock valued at $744,000 after acquiring an additional 3,809 shares during the period. Opinicus Capital Inc. grew its stake in shares of Bristol-Myers Squibb by 64.2% during the 1st quarter. Opinicus Capital Inc. now owns 13,599 shares of the biopharmaceutical company’s stock valued at $737,000 after acquiring an additional 5,319 shares during the period. Finally, Independence Bank of Kentucky grew its stake in shares of Bristol-Myers Squibb by 3.0% during the 1st quarter. Independence Bank of Kentucky now owns 10,556 shares of the biopharmaceutical company’s stock valued at $572,000 after acquiring an additional 308 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Up 0.0 %

NYSE:BMY traded up $0.02 during midday trading on Friday, hitting $41.53. 20,542,742 shares of the company traded hands, compared to its average volume of 15,934,426. The firm’s fifty day moving average is $42.97 and its 200-day moving average is $48.14. Bristol-Myers Squibb has a 12-month low of $39.63 and a 12-month high of $65.38. The firm has a market capitalization of $84.19 billion, a P/E ratio of -13.40, a P/E/G ratio of 14.20 and a beta of 0.43. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The business had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. During the same quarter last year, the firm posted $2.05 earnings per share. The business’s revenue was up 4.7% compared to the same quarter last year. On average, sell-side analysts predict that Bristol-Myers Squibb will post 0.58 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be paid a $0.60 dividend. The ex-dividend date of this dividend is Friday, July 5th. This represents a $2.40 dividend on an annualized basis and a yield of 5.78%. Bristol-Myers Squibb’s payout ratio is -77.42%.

Analyst Upgrades and Downgrades

BMY has been the subject of a number of recent research reports. Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Barclays cut their price objective on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. StockNews.com downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Thursday. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Finally, Wells Fargo & Company upped their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Bristol-Myers Squibb has an average rating of “Hold” and an average price target of $60.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.